{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:44:39Z","timestamp":1791557079107,"version":"4.3.4"},"reference-count":73,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2021,11,1]]},"DOI":"10.1001\/jamapsychiatry.2021.2130","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T15:02:06Z","timestamp":1629298926000},"page":"1238","source":"Crossref","is-referenced-by-count":97,"title":["Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia"],"prefix":"10.1001","volume":"78","author":[{"given":"Stefan","family":"Leucht","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany"},{"name":"Institute of Psychiatry, Psychology and Neuroscience, Department of Psychiatry, Department of Psychosis Studies, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany"},{"name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnim","family":"Hamza","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany"},{"name":"Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Salanti","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[{"name":"Psychiatric Institute, University of Illinois at Chicago"},{"name":"Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10202","key":"yoi210049r1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"9831","key":"yoi210049r2","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"yoi210049r3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/wps.v17.3","article-title":"Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis.","volume":"17","author":"Carbon","year":"2018","journal-title":"World Psychiatry"},{"issue":"10","key":"yoi210049r4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"yoi210049r5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1017\/S003329170002729X","article-title":"Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials.","volume":"24","author":"Bollini","year":"1994","journal-title":"Psychol Med"},{"issue":"2","key":"yoi210049r6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0165-1781(80)90028-1","article-title":"What is the best maintenance dose of neuroleptics in schizophrenia?","volume":"3","author":"Baldessarini","year":"1980","journal-title":"Psychiatry Res"},{"issue":"4","key":"yoi210049r7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/schbul\/sbp149","article-title":"Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.","volume":"37","author":"Uchida","year":"2011","journal-title":"Schizophr Bull"},{"issue":"4","key":"yoi210049r8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia.","volume":"177","author":"Leucht","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"5","key":"yoi210049r9","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1177\/0962280218773122","article-title":"One-stage dose-response meta-analysis for aggregated data.","volume":"28","author":"Crippa","year":"2019","journal-title":"Stat Methods Med Res"},{"issue":"2","key":"yoi210049r10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"yoi210049r11","first-page":"790","article-title":"The Brief Psychiatric Rating Scale.","volume":"10","author":"Overall","year":"1962","journal-title":"PsycholRep."},{"key":"yoi210049r12","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia.","volume":"8","author":"Ceraso","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"yoi210049r13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.schres.2012.10.015","article-title":"Interventions to reduce antipsychotic polypharmacy: a systematic review.","volume":"143","author":"Tani","year":"2013","journal-title":"Schizophr Res"},{"key":"yoi210049r14","article-title":"Antipsychotic dose reduction compared to dose continuation for people with schizophrenia.","author":"Bighelli","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"yoi210049r15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12874-018-0554-2","article-title":"Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study.","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"yoi210049r17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/jrsm.v10.3","article-title":"Pitfalls of using the risk ratio in meta-analysis.","volume":"10","author":"Bakbergenuly","year":"2019","journal-title":"Res Synth Methods"},{"issue":"8","key":"yoi210049r18","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.euroneuro.2012.11.004","article-title":"Equipercentile linking of the BPRS and the PANSS.","volume":"23","author":"Leucht","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"yoi210049r19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Flexible regression models with cubic splines.","volume":"8","author":"Durrleman","year":"1989","journal-title":"Stat Med"},{"issue":"2","key":"yoi210049r20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/schbul\/sbu001","article-title":"Dose equivalents for second-generation antipsychotics: the minimum effective dose method.","volume":"40","author":"Leucht","year":"2014","journal-title":"Schizophr Bull"},{"key":"yoi210049r21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.schres.2017.07.033","article-title":"Dose equivalents for second generation long-acting injectable antipsychotics: the minimum effective dose method.","volume":"193","author":"Rothe","year":"2018","journal-title":"Schizophr Res"},{"issue":"6","key":"yoi210049r22","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/schbul\/sbv037","article-title":"Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method.","volume":"41","author":"Leucht","year":"2015","journal-title":"Schizophr Bull"},{"key":"yoi210049r23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0022-3956(74)90071-5","article-title":"Dose equivalence of the antipsychotic drugs.","volume":"11","author":"Davis","year":"1974","journal-title":"J Psychiatr Res"},{"key":"yoi210049r24","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method.","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr Bull"},{"issue":"6","key":"yoi210049r25","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing.","volume":"167","author":"Gardner","year":"2010","journal-title":"Am J Psychiatry"},{"key":"yoi210049r27","doi-asserted-by":"publisher","first-page":"c4024","DOI":"10.1136\/bmj.c4024","article-title":"Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.","volume":"341","author":"Chen","year":"2010","journal-title":"BMJ"},{"issue":"10","key":"yoi210049r28","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry.","volume":"61","author":"Peters","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"7109","key":"yoi210049r29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"yoi210049r30","first-page":"1","article-title":"Multivariate dose-response meta-analysis: the dosresmeta R package.","volume":"72","author":"Crippa","year":"2016","journal-title":"J Statistical Software"},{"issue":"4","key":"yoi210049r31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial.","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"issue":"9","key":"yoi210049r32","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.","volume":"64","author":"Pigott","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"yoi210049r33","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","article-title":"A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg\/day for the treatment of patients with acute exacerbations of schizophrenia.","volume":"41","author":"McEvoy","year":"2007","journal-title":"J Psychiatr Res"},{"issue":"5","key":"yoi210049r34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.4088\/JCP.11m07530","article-title":"Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.","volume":"73","author":"Kane","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"yoi210049r35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1192\/bjp.bp.113.134213","article-title":"Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study.","volume":"205","author":"Fleischhacker","year":"2014","journal-title":"Br J Psychiatry"},{"issue":"1","key":"yoi210049r36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.schres.2013.06.041","article-title":"Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.","volume":"150","author":"Mallikaarjun","year":"2013","journal-title":"Schizophr Res"},{"issue":"3","key":"yoi210049r37","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1176\/ajp.156.3.412","article-title":"Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.","volume":"156","author":"Carpenter","year":"1999","journal-title":"Am J Psychiatry"},{"key":"yoi210049r38","first-page":"374","article-title":"Double-blind trial of fluphenazine decanoate against placebo in ambulant maintenance treatment of chronic schizophrenics.","volume":"14","author":"Dotti","year":"1979","journal-title":"Rivista di Psichiatria."},{"issue":"3","key":"yoi210049r39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/0165-1781(79)90016-7","article-title":"Low dose fluphenazine decanoate in maintenance treatment of schizophrenia.","volume":"1","author":"Kane","year":"1979","journal-title":"Psychiatry Res"},{"issue":"8","key":"yoi210049r40","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/archpsyc.1983.01790070083010","article-title":"Low-dose neuroleptic treatment of outpatient schizophrenics\u2014I: preliminary results for relapse rates.","volume":"40","author":"Kane","year":"1983","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"yoi210049r41","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/archpsyc.1983.01790220015002","article-title":"Costs and benefits of two doses of fluphenazine.","volume":"41","author":"Marder","year":"1984","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"yoi210049r42","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/archpsyc.1997.01830170079011","article-title":"Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment.","volume":"54","author":"Schooler","year":"1997","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"yoi210049r43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF00427763","article-title":"Prophylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of haloperidol and propericiazine.","volume":"82","author":"Nishikawa","year":"1984","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"yoi210049r44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/BF00432759","article-title":"Prophylactic effect of neuroleptics in symptom-free schizophrenics.","volume":"77","author":"Nishikawa","year":"1982","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"yoi210049r45","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1176\/ps.48.12.1571","article-title":"Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.","volume":"48","author":"Dellva","year":"1997","journal-title":"Psychiatr Serv"},{"issue":"3","key":"yoi210049r46","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0920-9964(01)00268-7","article-title":"Does cognitive function improve with quetiapine in comparison to haloperidol?","volume":"53","author":"Velligan","year":"2002","journal-title":"Schizophr Res"},{"issue":"4","key":"yoi210049r47","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1176\/appi.ajp.159.4.554","article-title":"A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia.","volume":"159","author":"Kane","year":"2002","journal-title":"Am J Psychiatry"},{"key":"yoi210049r48","first-page":"S7","article-title":"Minimal effective dose and relapse\u2014double-blind trial: haloperidol decanoate vs. placebo.","volume":"14","author":"Eklund","year":"1991","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"yoi210049r49","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/acp.1995.91.issue-4","article-title":"Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial.","volume":"91","author":"Huttunen","year":"1995","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"yoi210049r50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/0269881115620460","article-title":"A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.","volume":"30","author":"Tandon","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"2","key":"yoi210049r51","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1176\/appi.ajp.2009.07081221","article-title":"Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.","volume":"167","author":"Kane","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"6","key":"yoi210049r52","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.pnpbp.2009.05.014","article-title":"Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.","volume":"33","author":"Hough","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"yoi210049r53","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.4088\/JCP.v67n0804","article-title":"A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.","volume":"67","author":"Simpson","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"yoi210049r54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study.","volume":"17","author":"Arato","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"yoi210049r55","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s002130000452","article-title":"Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.","volume":"150","author":"Cooper","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"yoi210049r56","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","article-title":"Estimating dopamine D2 receptor occupancy for doses of 8 antipsychotics: a meta-analysis.","volume":"33","author":"Lako","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"yoi210049r57","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41386-019-0573-7","article-title":"Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.","volume":"45","author":"Tani","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"yoi210049r58","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/archpsyc.1976.01770070088010","article-title":"Comparative doses and costs of antipsychotic medication.","volume":"33","author":"Davis","year":"1976","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"yoi210049r59","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/pcn.2018.72.issue-9","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study.","volume":"72","author":"Ishigooka","year":"2018","journal-title":"Psychiatry Clin Neurosci"},{"issue":"5","key":"yoi210049r60","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/schbul\/sbt090","article-title":"Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.","volume":"39","author":"Takeuchi","year":"2013","journal-title":"Schizophr Bull"},{"key":"yoi210049r61","article-title":"Increasing antipsychotic dose for non response in schizophrenia.","volume":"5","author":"Samara","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"yoi210049r62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/archpsyc.1988.01800250095013","article-title":"Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.","volume":"45","author":"Baldessarini","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"yoi210049r63","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41386-018-0278-3","article-title":"Does relapse contribute to treatment resistance? antipsychotic response in first- vs. second-episode schizophrenia.","volume":"44","author":"Takeuchi","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"yoi210049r64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","article-title":"Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia.","volume":"138","author":"Emsley","year":"2012","journal-title":"Schizophr Res"},{"issue":"1-3","key":"yoi210049r65","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2013.05.016","article-title":"The evidence for illness progression after relapse in schizophrenia.","volume":"148","author":"Emsley","year":"2013","journal-title":"Schizophr Res"},{"issue":"1","key":"yoi210049r66","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/JCP.0b013e31827bfcc1","article-title":"Comparison of treatment response in second-episode versus first-episode schizophrenia.","volume":"33","author":"Emsley","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"yoi210049r67","first-page":"315","article-title":"A comparison of European and American dosing regimens of schizophrenic patients on clozapine: efficacy and side effects.","volume":"31","author":"Pollack","year":"1995","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"yoi210049r68","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/(ISSN)1098-2396","article-title":"D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period.","volume":"40","author":"Joyce","year":"2001","journal-title":"Synapse"},{"issue":"2","key":"yoi210049r69","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1001\/jamapsychiatry.2020.2166","article-title":"Tapering antipsychotic treatment.","volume":"78","author":"Horowitz","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"yoi210049r71","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","article-title":"Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis.","volume":"31","author":"Uchida","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"yoi210049r72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009479","article-title":"Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.","volume":"5","author":"Brunoni","year":"2010","journal-title":"PLoS One"},{"issue":"1-02","key":"yoi210049r73","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017.","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"yoi210049r26","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"Harrell","year":"2015"},{"key":"yoi210049r70","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-3-642-86922-8_19","volume-title":"Guidelines for Neuroleptic Relapse Prevention in Schizophrenia","author":"Kissling","year":"1991"},{"key":"yoi210049r16","unstructured":"Higgins? JPT, Thomas? J, Chandler? J, Cochrane Handbook for Systematic Reviews of Interventions, version 6.1. September 2020. Accessed November 15, 2020. http:\/\/www.training.cochrane.org\/handbook"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2783296\/jamapsychiatry_leucht_2021_oi_210049_1635884826.90133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T15:35:22Z","timestamp":1673105722000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2783296"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.2130","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}